Effects of pitavastatin on the expression of VCAM-1 and its target gene miR-126 in cultured human umbilical vein endothelial cells

Cardiovascular Therapeutics

Volumn 32, Issue 5, 2014, Pages 193-197

  Xu, Qinglu ^a   Luan, Tianzhu ^a   Fu, Songbin ^b   Yang, Jian ^a   Jiang, Chao ^a   Xia, Fangfang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Endothelial cells; MiR 126; Pitavastatin; Vascular cell adhesion molecule 1

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICRORNA; MIRN126 MICRORNA, HUMAN; PITAVASTATIN; QUINOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; CELL CULTURE; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL;

ATHEROSCLEROSIS; CELLS, CULTURED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICRORNAS; QUINOLINES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84908398718     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12081     Document Type: Article

References (26)

1. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009;27:165-197.
2. Mendivil CO, Rimm EB, Furtado J, et al. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 2011; 124:2065-2072.
3. Scheffer PG, Teerlink T, Dekker JM, et al. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study. Clin Chem 2008;54:1325-1330.
4. Sol EM, Sundsten T, Bergsten P. Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells. Lipids Health Dis 2009;8:3.
5. Holmberg R, Refai E, Hoog A, et al. Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci USA 2011;108:10685-10689.
6. Zheng C, Khoo C, Furtado J, et al. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 2010;121:1722-1734.
7. Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol 2012;73:518-535.
8. Cicha I, Beronov K, Ramirez EL, et al. Shear stress preconditioning modulates endothelial susceptibility to circulating TNF-alpha and monocytic cell recruitment in a simplified model of arterial bifurcations. Atherosclerosis 2009;207:93-102.
9. Kim YS, Ahn Y, Hong MH, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and nuclear factor kappaB in endothelial cells. J Cardiovasc Pharmacol 2007;49:376-383.
10. Eccles KA, Sowden H, Porter KE, et al. Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis 2008;200:69-79.
11. Rao RM, Yang L, Garcia-Cardena G, et al. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res 2007;101:234-247.
12. Storling J, Juntti-Berggren L, Olivecrona G, et al. Apolipoprotein CIII reduces proinflammatory cytokine-induced apoptosis in rat pancreatic islets via the Akt prosurvival pathway. Endocrinology 2011;152:3040-3048.
13. Leuci D, Pomarico G, Casucci N, et al. Primary prophylaxis of esophageal variceal bleeding in cirrhotic patients. Recenti Prog Med 2008;99:607-610.
14. Klein S, Van Beuge MM, Granzow M, et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol 2012;57:1220-1227.
15. Bai T, Lian L, Wu Y, et al. Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells. Int Immunopharmacol 2013;15:275-281.
16. Jiang J, Ge X, Li Z, et al. MicroRNA-281 regulates the expression of ecdysone receptor (EcR) isoform B in the silkworm, Bombyx mori. Insect Biochem Mol Biol 2013;43:692-700.
17. Guo J, Pan Q, Li D, et al. MiR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. J Hepatol 2009;50:766-778.
18. Dooley S, Hamzavi J, Ciuclan L, et al. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology 2008;135:642-659.
19. Meister J, Schmidt MH. MiR-126 and miR-126/: new players in cancer. Sci World J 2010;10: 2090-2100.
20. Zhang J, Du Y, Lin F, et al. The cell growth suppressor, miR-126, targets IRS-1. Biochem Biophys Res Commun 2008;377:136-140.
21. Feng R. MiR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 2010;298:50-63.
22. Nikolic I, Plate KH, Schmidt MH, et al. EGFL7 meets miRNA-126: an angiogenesis alliance. J Angiogenes Res 2010;2:9.
23. Liu Y. PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling. Lab Invest 2009;89:209-221.
24. Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 2010;53:976-980.
25. Liang J, Deng X, Lin Z, et al. Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis. World J Gastroenterol 2009;15:4529-4537.
26. Liu B, Peng XC, Zheng L, et al. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 2009;66:169-175.